24979-715 : Sorafenib 200 mg Oral Tablet, Film Coated


NDC: 24979-715
Labeler: Twi Pharmaceuticals USA, Inc.
Product Type: Human Prescription Drug
Drug Name: Sorafenib
Dosage Form: Oral Tablet, Film Coated
Application #: ANDA209050
Rev. Date: 


NDC Package Codes:

  • 24979-715-04: 60 TABLET, FILM COATED IN 1 BOTTLE (24979‑715‑04)
  • 24979-715-44: 120 TABLET, FILM COATED IN 1 BOTTLE (24979‑715‑44)

Active Ingredients:

  • Sorafenib

Dosage Strength:

  • 200 mg

Pharmaceutical Classes:

  • Kinase Inhibitor [EPC]
  • Protein Kinase Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 0480-5425 Sorafenib 200 mg Oral Tablet, Film Coated by Teva Pharmaceuticals, Inc.
  • 13668-682 Sorafenib 200 mg Oral Tablet, Film Coated by Torrent Pharmaceuticals Limited
  • 43598-458 Sorafenib 200 mg Oral Tablet, Film Coated by Dr.reddys Laboratories Inc
  • 43826-066 Sorafenib 200 mg Oral Tablet, Film Coated by Bora Pharmaceutical Laboratories Inc.
  • 51407-760 Sorafenib 200 mg Oral Tablet, Film Coated by Golden State Medical Supply, Inc.
  • 51990-201 Sorafenib 200 mg Oral Tablet, Film Coated by Yabao Pharmaceutical Co., Ltd. Beijing

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 24979-715 QR Code

< Prev: 24979-710Next: 24979-722 >

Related Discussions:

How many people in USA using Sorafenib Tosylate?
Hi, Does anyone know how many people take this medicine in USA? How about its effect? How mean generally how long it can... 2 replies
sorafeniband side effects
Been on it for 9 months. Acne on the face became bad and lowered dose. Wondering if that's OK with the b17 and sours...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.